Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer

• DOI: 10.1111/cas.13890
• Publication Date: 2018-11-23T09:25:45Z
• Authors: Kazuhiko Hayashi; Naoyoshi Yamamoto; Mio Nakajima; Akihiro Nomoto; Hiroshi Tsuji; Kazuhiko Ogawa; Tadashi Kamada
• Keywords: Pneumonitis; Carbon Ion Radiotherapy

The efficacy and safety of carbon‐ion radiotherapy ( CIRT ) for locally advanced non‐small‐cell lung cancer LA ‐ NSCLC remain unclear. We reported the clinical outcomes . Data 141 eligible patients who received between 1995 2015 were retrospectively analyzed. Local control LC ), locoregional LRC progression‐free survival PFS overall (OS calculated using Kaplan‐Meier method. median age was 75.0 years. Overall, 21 (14.9%), 57 (40.4%), 43 (30.5%) 20 (14.2%) had T1, T2, T3 T4 disease, respectively. Moreover, 51 (36.2%), 45 (31.9%), 40 (28.4%) 5 (3.5%) N0, N1, N2 N3 Furthermore, 34 (24.1%), 42 (29.8%), (31.9%) stages IIA , IIB IIIA ΙΙΙB 62 (44.0%), 60 (42.6%), 8 (5.7%) 11 (7.8%) adenocarcinoma, squamous cell carcinoma, large others, dose 72.0 Gy (relative biological effectiveness). No patient concurrent chemotherapy. Median follow‐up periods 29.3 (1.6‐207.7) 40.0 (10.7‐207.7) months all survivors, Two‐year OS rates 80.3%, 40.2% 58.7%, 1 (0.7%), (0.7%) developed Grades 4 (mediastinal hemorrhage), 3 (radiation pneumonitis) (bronchial fistula) toxicities, Multivariate analysis showed adenocarcinoma N2/3 classification as significant poor prognosticators is an effective treatment with acceptable toxicity especially elderly or severe comorbidities cannot be treated surgery chemoradiotherapy.